The Experts below are selected from a list of 72 Experts worldwide ranked by ideXlab platform
Alastair Gray - One of the best experts on this subject based on the ideXlab platform.
-
a macroeconomic assessment of the impact of medical Research Expenditure a case study of nihr biomedical Research centres
PLOS ONE, 2019Co-Authors: Alastair Gray, Joel Smith, Keith M Channon, Vasiliki Kiparoglou, John F ForbesAbstract:Quantifying the value of investment in medical Research can inform decision-making on the prioritisation of Research programmes. Existing methodologies to estimate the rate of return of medical Research are inappropriate for early-phase translational Research due to censoring of health benefits and time lags. A strategy to improve the process of translational Research for patient benefit has been initiated as part of the UK National Institute for Health Research (NIHR) investment in Biomedical Research Centres (BRCs) in England. By providing a platform for partnership between universities, NHS trusts and industry, successful BRCs should reduce time lags within translational Research whilst also providing an impetus for local economic growth through industry collaboration. We present a novel contribution in the assessment of early-phase biomedical Research by estimating the impact of the Oxford Biomedical Research Centre (OxBRC) on income and job creation following the initial NIHR investment. We adopt a macroeconomic assessment approach using Input-Output Analysis to estimate the value of medical Research in terms of income and job creation during the early pathway towards translational biomedical Research. Inter-industry linkages are assessed by building a model economy for the South East England region to estimate the return on investment of the OxBRC. The results from the input-output model estimate that the return on investment in biomedical Research within the OxBRC is 46%. Each £1 invested in the OxBRC generates an additional £0.46 through income and job creation alone. Multiplicative employment effects following a marginal investment in the OxBRC of £98m during the period 2007-2017 result in an estimated additional 196 full time equivalent positions being created within the local economy on top of direct employment within OxBRC. Results from input-output analyses can be used to inform the prioritisation of biomedical Research programmes when compared against national minimum thresholds of investment.
-
uk Research Expenditure on dementia heart disease stroke and cancer are levels of spending related to disease burden
European Journal of Neurology, 2012Co-Authors: Ramon Luengofernandez, Jose Leal, Alastair GrayAbstract:Background and purpose: A UK government review recommended that the impact of disease on the population and economy should be assessed to inform health Research priorities. This study aims to quantify UK governmental and charity Research funding for dementia, cancer, coronary heart disease (CHD) and stroke in 2007/08 and assess whether the levels of Research Expenditure are aligned with disease and economic burden. Methods: We identified UK governmental agencies and charities providing health Research funding and determined their levels of funding for dementia, cancer, CHD and stroke. Research funding levels were compared to the number of cases, disability-adjusted life years (DALYs) and economic burden. Economic costs were estimated using data on morbidity, mortality, health and social care use, private costs and other related indicators. Results: Research funding to the four diseases was £833 million, of which £590 million (71%) was devoted to cancer, £169 million (20%) to CHD, £50 million (6%) to dementia and £23 million (4%) to stroke. Cancer received £482 in Research funding per 1000 DALYs lost, CHD received £266, dementia received £166, with stroke receiving £71. In terms of economic burden, for every £1 million of health and social care costs attributable to each disease, cancer received £129 269 in Research funding, CHD received £73 153, stroke received £8745 and dementia received £4882. Conclusions: Most health Research funding in the UK is currently directed towards cancer. When compared to their burden, our analysis suggests that Research spending on dementia and stroke is severely underfunded in comparison with cancer and CHD.
Keith M Channon - One of the best experts on this subject based on the ideXlab platform.
-
a macroeconomic assessment of the impact of medical Research Expenditure a case study of nihr biomedical Research centres
PLOS ONE, 2019Co-Authors: Alastair Gray, Joel Smith, Keith M Channon, Vasiliki Kiparoglou, John F ForbesAbstract:Quantifying the value of investment in medical Research can inform decision-making on the prioritisation of Research programmes. Existing methodologies to estimate the rate of return of medical Research are inappropriate for early-phase translational Research due to censoring of health benefits and time lags. A strategy to improve the process of translational Research for patient benefit has been initiated as part of the UK National Institute for Health Research (NIHR) investment in Biomedical Research Centres (BRCs) in England. By providing a platform for partnership between universities, NHS trusts and industry, successful BRCs should reduce time lags within translational Research whilst also providing an impetus for local economic growth through industry collaboration. We present a novel contribution in the assessment of early-phase biomedical Research by estimating the impact of the Oxford Biomedical Research Centre (OxBRC) on income and job creation following the initial NIHR investment. We adopt a macroeconomic assessment approach using Input-Output Analysis to estimate the value of medical Research in terms of income and job creation during the early pathway towards translational biomedical Research. Inter-industry linkages are assessed by building a model economy for the South East England region to estimate the return on investment of the OxBRC. The results from the input-output model estimate that the return on investment in biomedical Research within the OxBRC is 46%. Each £1 invested in the OxBRC generates an additional £0.46 through income and job creation alone. Multiplicative employment effects following a marginal investment in the OxBRC of £98m during the period 2007-2017 result in an estimated additional 196 full time equivalent positions being created within the local economy on top of direct employment within OxBRC. Results from input-output analyses can be used to inform the prioritisation of biomedical Research programmes when compared against national minimum thresholds of investment.
Joel Smith - One of the best experts on this subject based on the ideXlab platform.
-
a macroeconomic assessment of the impact of medical Research Expenditure a case study of nihr biomedical Research centres
PLOS ONE, 2019Co-Authors: Alastair Gray, Joel Smith, Keith M Channon, Vasiliki Kiparoglou, John F ForbesAbstract:Quantifying the value of investment in medical Research can inform decision-making on the prioritisation of Research programmes. Existing methodologies to estimate the rate of return of medical Research are inappropriate for early-phase translational Research due to censoring of health benefits and time lags. A strategy to improve the process of translational Research for patient benefit has been initiated as part of the UK National Institute for Health Research (NIHR) investment in Biomedical Research Centres (BRCs) in England. By providing a platform for partnership between universities, NHS trusts and industry, successful BRCs should reduce time lags within translational Research whilst also providing an impetus for local economic growth through industry collaboration. We present a novel contribution in the assessment of early-phase biomedical Research by estimating the impact of the Oxford Biomedical Research Centre (OxBRC) on income and job creation following the initial NIHR investment. We adopt a macroeconomic assessment approach using Input-Output Analysis to estimate the value of medical Research in terms of income and job creation during the early pathway towards translational biomedical Research. Inter-industry linkages are assessed by building a model economy for the South East England region to estimate the return on investment of the OxBRC. The results from the input-output model estimate that the return on investment in biomedical Research within the OxBRC is 46%. Each £1 invested in the OxBRC generates an additional £0.46 through income and job creation alone. Multiplicative employment effects following a marginal investment in the OxBRC of £98m during the period 2007-2017 result in an estimated additional 196 full time equivalent positions being created within the local economy on top of direct employment within OxBRC. Results from input-output analyses can be used to inform the prioritisation of biomedical Research programmes when compared against national minimum thresholds of investment.
Vasiliki Kiparoglou - One of the best experts on this subject based on the ideXlab platform.
-
a macroeconomic assessment of the impact of medical Research Expenditure a case study of nihr biomedical Research centres
PLOS ONE, 2019Co-Authors: Alastair Gray, Joel Smith, Keith M Channon, Vasiliki Kiparoglou, John F ForbesAbstract:Quantifying the value of investment in medical Research can inform decision-making on the prioritisation of Research programmes. Existing methodologies to estimate the rate of return of medical Research are inappropriate for early-phase translational Research due to censoring of health benefits and time lags. A strategy to improve the process of translational Research for patient benefit has been initiated as part of the UK National Institute for Health Research (NIHR) investment in Biomedical Research Centres (BRCs) in England. By providing a platform for partnership between universities, NHS trusts and industry, successful BRCs should reduce time lags within translational Research whilst also providing an impetus for local economic growth through industry collaboration. We present a novel contribution in the assessment of early-phase biomedical Research by estimating the impact of the Oxford Biomedical Research Centre (OxBRC) on income and job creation following the initial NIHR investment. We adopt a macroeconomic assessment approach using Input-Output Analysis to estimate the value of medical Research in terms of income and job creation during the early pathway towards translational biomedical Research. Inter-industry linkages are assessed by building a model economy for the South East England region to estimate the return on investment of the OxBRC. The results from the input-output model estimate that the return on investment in biomedical Research within the OxBRC is 46%. Each £1 invested in the OxBRC generates an additional £0.46 through income and job creation alone. Multiplicative employment effects following a marginal investment in the OxBRC of £98m during the period 2007-2017 result in an estimated additional 196 full time equivalent positions being created within the local economy on top of direct employment within OxBRC. Results from input-output analyses can be used to inform the prioritisation of biomedical Research programmes when compared against national minimum thresholds of investment.
Jonathan Grant - One of the best experts on this subject based on the ideXlab platform.
-
quantifying the economic impact of government and charity funding of medical Research on private Research and development funding in the united kingdom
BMC Medicine, 2016Co-Authors: Jon Sussex, Yan Feng, Jorge Mestreferrandiz, Michele Pistollato, Marco Hafner, Peter Burridge, Jonathan GrantAbstract:Background Government- and charity-funded medical Research and private sector Research and development (R&D) are widely held to be complements. The only attempts to measure this complementarity so far have used data from the United States of America and are inevitably increasingly out of date. This study estimates the magnitude of the effect of government and charity biomedical and health Research Expenditure in the United Kingdom (UK), separately and in total, on subsequent private pharmaceutical sector R&D Expenditure in the UK.